BioNTech-Pfizer raises annual coronavirus vaccine output goal to 2.5 bln doses
BioNTech said on Tuesday that it and partner Pfizer would increase manufacturing capacity of their COVID-19 vaccine to 2.5 billion doses by the end of 2021, unveiling for the first time projected sales of close to 10 billion euros ($11.73 billion) from the product this year.
Pfizer previously said the two partners would likely produce between 2.3 billion and 2.4 billion doses this year.
For more coronavirus news, visit our dedicated page.
BioNTech cited its new facility in the German city of Marburg and an expansion of the pair’s network of third-party manufacturers and suppliers as drivers behind the larger volumes.
For all the latest headlines follow our Google News channel online or via the app.
“Additional measures and discussions with potential partners to further expand the manufacturing capacity and network are ongoing,” it added.
As of last week, more than 200 million doses of the product, known as BNT162b2 or Comirnaty, have been supplied, while signed orders for delivery in 2021 currently amount to 1.4 billion doses, said BioNTech.
Based on this order backlog, BioNTech said it expected 9.8 billion euros in revenues from the product, reflecting direct sales, sales to collaboration partners, milestone payments from partners as well as a share of gross profit in the partners’ territories.
BioNTech has previously said it had a 50-50 cost and profit share agreement with Pfizer, which excludes China, and a 35 percent to
40 percent gross profit share deal with Fosun Pharma in China.
In early February, Pfizer projected Comirnaty would contribute at least $15 billion to its 2021 group sales.
Read more:
Pfizer, Moderna vaccines reduce COVID-19 infection risk by 90 percent: US study
Pfizer to consider vaccine sites outside US, Europe only after pandemic supply phase
Pfizer, BioNTech begin testing COVID-19 vaccine in children under 12
-
Pfizer, Moderna vaccines reduce COVID-19 infection risk by 90 percent: US study
The Pfizer and Moderna COVID-19 vaccines were shown to be 90 percent effective against coronavirus infection – regardless of symptom status – in a ... Coronavirus -
Pfizer, BioNTech begin testing COVID-19 vaccine in children under 12
Pfizer Inc and German partner BioNTech SE began testing their COVID-19 vaccine in children under 12, with hopes of expanding vaccination to that age ... Coronavirus -
Pfizer begins human testing of new COVID-19 pill
Pfizer Inc. said it has begun human safety testing of a new pill to treat the coronavirus that could be used at the first sign of illness.If it ... Coronavirus -
Pfizer to deliver 200 mln doses of COVID-19 vaccine in Q2: EU Commission
The European Commission expects to receive more than 200 million doses of COVID-19 vaccine from Pfizer and BioNTech in the second quarter, it said on ... Coronavirus -
Brazil signs Pfizer deal for 100 mln COVID-19 vaccine doses
Brazil has signed a deal with Pfizer Inc to purchase 100 million doses of its COVID-19 vaccine, a person with direct knowledge of the matter said on ... Coronavirus -
Pfizer to consider vaccine sites outside US, Europe only after pandemic supply phase
Pfizer Inc will consider making its coronavirus vaccine outside the United States and Europe only after the “pandemic supply phase” is over, it said ... Coronavirus -
Pfizer seeks to make vaccine in India if assured of faster clearance, export freedom
Pfizer Inc has told the Indian government it wants to produce its coronavirus vaccine locally if assured of faster regulatory clearance andfreedom on ... Coronavirus